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Abstract:  
 
Diabetes mellitus and heart disease are prevalent in the United States and around the world. 
Especially with the aging population, it is vital to understand the potential risks associated 
with diabetes, specifically type 2 diabetes mellitus. Hyperglycemia is an established risk 
factor for heart disease. Our study aims to understand the effects of hyperglycemia on 
secretion of PLGF, a biomarker for heart disease. In our study, we tested cells in both a 
hyperglycemic and healthy environment, and used mannitol as a control for 
hyperosmolarity. We hypothesized that treatment of human vascular cells with H2S would 
decrease secretion of the pro-atherogenic cytokine, PLGF. We further hypothesized that 
hyperglycemia (a risk factor for cardiovascular disease) would increase secretion of PLGF 
by vascular cells and that H2S treatment would reverse this effect. 
 We found that in both mannitol and hyperglycemic environments, PLGF secretion 
increased significantly. This implies that hyperosmolarity itself rather than specifically 
hyperglycemic conditions increase PLGF secretion. Additionally, we found that hydrogen 
sulfide treatment in increasing doses reversed the increase in PLGF secretion upon 
hyperglycemic conditions. This supports our hypothesis that treatment of human vascular 
cells with hydrogen sulfide would decrease secretion of PLGF, and that hyperglycemia 
would increase secretion of PLGF. These findings are potentially applicable to the 
hyperosmolar hyperglycemic state sometimes associated with uncontrolled diabetes 
mellitus. Further understanding of this mechanism could lead to potential clinical treatment 
of this condition using H2S donating drugs.   
 
I. Beginning goals and objectives: 
 
Rationale for our study 
Heart disease is the number one killer in the US, with coronary heart disease being the 
most common type. Coronary heart disease kills over 370,000 people every year in the 
US1. Although prevalent, the distribution of deaths annually varies regionally. Oklahoma 
has one of the highest rates of death from coronary heart disease1. Hyperglycemia also has 
a high incidence rate in Oklahoma and is an established risk factor for heart disease, as it 
is can contribute to the formation of atherosclerotic plaques in coronary arteries1. 
Atherosclerosis is a gradual process whereby arteries become increasingly narrow due 
to the presence of fatty plaques in the arterial wall that protrude into the vessel space and 
compromise blood flow to distal regions1. This is a result of irritants such as 
hyperlipidemia, high blood pressure, smoking, and hyperglycemia. The development of 
atherosclerotic plaques over time is supported by the formation of microvessels within the 
plaques.  This formation of new blood vessels is known as “angiogenesis”. 
PLGF is a multi-functional, angiogenic cytokine that contributes to the early 
progression of atherosclerosis ("atherogenic") although the mechanism is not fully 
understood. Likewise, PLGF is now an established clinical biomarker for cardiovascular 
disease4.  We are interested in ways to potentially minimize its effects on the progression 
of atherosclerosis. 
Potential for cardio-protective therapeutic drugs has increased with recent discovery of 
the importance of gaseous mediators in the body. Examples of these include nitric oxide, 
carbon monoxide, and hydrogen sulfide (H2S). These gaseous mediators are endogenously 
produced at low concentrations, and each participates in vasodilation and cardioprotection.  
Hydrogen sulfide, although commonly known as a respiratory poison, has actually been 
recently discovered to act (at physiological concentrations) as a cardioprotectant in the 
body. H2S is endogenously produced at low concentrations by the enzyme 
cysthathionineγlyase (CSE) in our blood vessels and exerts a number of properties 
including anti-atherogenic,anti-oxidative , and vasodilatory action2. The effect of hydrogen 
sulfide on PLGF is unknown, however the protective properties of this gas make it a strong 
candidate to potentially alleviate the atherogenic effect of PLGF.  Since hyperglycemia is 
a common risk factor for atherosclerosis, we choose to mimic diabetic conditions in vitro 
to test the effect on PLGF secretion and the impact of treatment with hydrogen sulfide.  We 
also tested vascular cells from healthy versus diabetic donors to assess CSE gene 
expression, which would suggest changes in endogenous production of hydrogen sulfide. 
 
Background on hyperosmolar hyperglycemic state  
 Hyperosmolar hyperglycemic state (HHS) is a serious acute complication 
associated with diabetes mellitus type 25. This state is often associated with patients with 
concomitant illness that reduces fluid intake5. This could include infection, but could also 
include dehydration, altered mental state, or most commonly cardiovascular disease3,5. 
HHS is usually an issue in older patients, and exerts a higher mortality rate  relative to 
diabetic ketoacidosis (DKA). HHS often can be difficult to differentiate between the 
original illnesses, rendering it almost impossible to diagnose3.  
 HHS is characterized by hyperglycemia, plasma hyperosmolarity, and dehydration 
in patients5.  Additionally, it can cause disorientation in mental state5. Clinically, one-third 
of DKA and HHS cases overlap, which implies that both states of diabetes mellitus differ 
only in amount of dehydration and presence of acidosis3.  
 Hyperosmolar hyperglycemic state occurs in the absence of ketoacidosis, however 
it follows the same pathway as DKA5. The difference is the cause of HSS is hyperglycemia 
rather than ketoacidosis5. DKA takes hours to develop, but HHS takes days, as it is more 
extreme6. Hyperglycemia in diabetes mellitus combined with a rise in plasma proteins 
cause the hyperosmolar state3. Due to this state, antidiuretic hormone is released, relieving 
renal water loss3. This also causes stimulation in thirst3. In HHS, drinking water cannot 
compensate for renal water loss3. This severe dehydration causes hypovolemia, leading to 
hypotension and impaired tissue perfusion3. The end stage of HHS is coma due to 
electrolyte disturbances in result of hypvolemia3. Severe hyperosmolarity causes a 
stimulation of renin-angiotensin-aldosterone system and can lead to a total shutdown of the 
renal system3. In this state, oliguria prevents excretion of glucose, which in turn 





We hypothesized that treatment of human vascular cells with H2S would decrease secretion 
of the pro-atherogenic cytokine, PLGF. We further hypothesized that hyperglycemia (a 
risk factor for cardiovascular disease) would increase secretion of PLGF by vascular cells 
and that H2S treatment would reverse this effect. 
 
II. Experiments performed: 
 
Culturing cells 
Primary pooled human umbilical vein endothelial cells (HUVEC) were purchased 
from Lonza (Walkersville, MD, USA)  and grown in EBM-2 medium supplemented with 
growth factors and 2.5% FBS (Lonza).  Cells were cultured at 37° C in 5% CO2 until 85% 
confluent then sub-cultured into 6 well plates for experimental procedures.  HUVEC were 
cultured in 6 well plates for three days.  Each day cells were treated with fresh media 
containing either normal glucose (5mM) as a control, mannitol (20mM) to control for 
hyperosmolarity, or high glucose (25mM) to mimic chronic hyperglycemia.  Following the 
three day period, all cells were treated with varying doses (0, 50, 100, 150, 200 uM) of 
sodium hydrosulfide (NaHS), which liberates hydrogen sulfide gas, for six hours. Culture 
media was collected on ice in tubes containing protease inhibitor for quantification of 
secreted PLGF, an atherogenic cytokine.  In addition, cells were harvested and lysed to 
isolate RNA for downstream gene expression studies. 
ELISA 
Sample medium was added to each well of the Enzyme-Linked Immunosorbent 
Assay (ELISA) plate, which was coated with the capture antibody of interest (PLGF) and 
incubated for 2 hours at room temperature.  The wells were washed 4X followed by the 
addition of detection antibody and incubation at room temperature for 2 hours.  The 
detection antibody is linked to Streptavidin-HRP which allows for a colorimetric reaction 
to occur upon the addition of substrate solution and 20 minute incubation at room 
temperature. Stop solution was then added to each well and the absorbance was measured 
at 450 nm using a microplate reader. In addition, in order to normalize the secretion 
(pg/mL) of our target protein in relation to the overall protein (mg/mL) to account for 
overall changes in protein concentration, we used Bicinchoninic Acid Protein Assay (BCA).  
This assay induces a colorimetric reaction that measures total protein in the samples. This 
depends on two reactions.  First, the peptide bonds in the protein must reduce the Cu2+ ions 
to Cu+ from the cupric sulfate. This amount of reduction is in proportion to the total amount 
of protein in the solution. Second, two molecules of bicinchoninic acid then react with the 
Cu+ ions. This reaction induces a purple color, which absorbs light at a specific wavelength. 
This complex is reliant upon presence of side chains of cysteine, tyrosine, and tryptophan. 
The total protein present was then quanitified. We quantify this by measuring the spectra 
at 540 nm. We then compared these with the spectra known concentrations of protein 
solutions using a microplate reader.  
 
RNA isolation & cDNA synthesis 
In order to measure the expression of CSE,  RNA was isolated from diabetic versus 
nondiabetic cells by our collaborator (Dr. Nabil Rashdan) using RNeasy columns from 
Qiagen; then we reverse transcribed the RNA  into cDNA. .  
 In order to synthesize cDNA we first treated the cDNA with gDNA Wipeout 
Buffer. This removes any genomic DNA that could potentially contaminate the sample of 
RNA. To convert the RNA sample to cDNA, we added the enzyme reverse transcriptase 
to reverse transcribe the cDNA. To do this, we added a mastermix of Quantiscrupt RT, 
Quanitscript RT Buffer, and RT Primer Mix to microvials and added RNA samples. We 
then places the microtubes into the G-Storm Cycler for 15 minutes at 42°C then for 3 




In order to measure gene expression by the donor cells, we used quantitative real 
time PCR (qPCR). We first made a master mix containing SYBR green (an intercalating 
dye), forward primer and reverse primer for the target genes (CSE and beta-actin), and 
molecular grade water. The primers bind to CSE gene in the cDNA. DNA polymerase 
synthesizes copies of this specific region of the CSE gene. SYBR green dye is fluorescent 
and intercalates the DNA while the CSE cDNA is amplified using the Eppendorf 
Mastercyler. This fluorescence increases during this process anddirectly correlates with the 
increase of CSE gene expression. The signal was analyzed using EppendorfRealPlex 
software. We used the delta delta Ct method to analyze the data of both the EC and CASMC 




Figure 1. PLGF protein secretion by human endothelial cells (EC) following chronic 
hyperglycemic/hyperosmolar conditions.   EC were treated with either normal glucose  
(5mM), mannitol (20mM), high glucose (25mM) for 3 days.  Then varying doses of NaHS were 
added to the EC. Six hours later, medium was collected and secreted PLGF protein was 
measured by ELISA (n=2).  
 
  
Figure 2. CSE expressed by endothelial cells (EC) in diabetic donors. 
 
  
Figure 3. CSE expressed by Coronary Artery Smooth Muscle Cells (CASMC )in diabetic 
donors. 
 
Interpretation of Data 
We previously found that CSE gene expression is increased following shear stress 
patterns similar to blood flow in atherosclerotic arteries suggesting CSE is up-regulated to 
produce the cardioprotective gas, H2S. In this study, hyperosmolarity substantially 
increased the secretion of PLGF by human endothelial cells. Hyperglycemic conditions 
produced an increase in PLGF protein expression, but this may be due strictly to changes 
in osmolarity rather than a glucose-specific response.Induction of PLGF protein secretion 
was abolished by treatment with 100-200μM NaHS, which liberates H2S gas. Other studies 
show that hyperosmolarity drives oxidative pathways, suggesting that the observed 
induction of PLGF expression by hyperosmolarity in our study may be due to oxidative 




















































































p38MAPK and JNK, which are key players in oxidative stress pathways and support our 
findings herein.  
 In addition, using cells from diabetic donors, we have found an increase in CSE 
gene expression in endothelial cells of diabetic donors. We suggest that this increase in 
expression is due to the correlation of hyperglycemia with atherosclerotic conditions, 
which increases the need to dilate the vessels, a task that could theoretically be 
accomplished through an increase in endogenously produced hydrogen sulfide. These 
results could potentially be applied to HHS conditions. To specifically apply our findings 
to HHS, future studies may include measuring the effect of H2S treatment onEC exposed 
to  mannitol alone or mannitol plus hyperglycemic conditions. This could potentially help 
us to understand the pathway of HHS, and potential treatment to decrease severity of or 
stop HHS in uncontrolled diabetes mellitus.  
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